Recently, we have shown that combined treatment with the CDK4/6 inhibitor abemaciclib and the EZH2 inhibitors GSK126 or tazemetostat led to synergistic antitumor effects in preclinical GBM models [24]. Here, CDK4 is linked to glioblastoma.